Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly: Ive Learned Not To Fight Against The Market (Downgrade)

…

Can LLYs Next-Generation Obesity Pipeline Fuel Further Growth?

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.…

Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate

…

Teslas Robotaxi Rollout

In this podcast, Motley Fool Chief Investment Officer Andy Cross and contributors Jason Hall and Matt Frankel discuss: Fair Isaac Corp.…

3 Reasons to Buy Eli Lilly Stock Like Theres No Tomorrow

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results…

Abbott jumps on RFK Jr. health push — plus, reviews of Eli Lillys obesity drug data

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly: It Is A Bet On Human Longevity

…

Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.…

IWF Is a Great Choice for Most, But I Like VUG ETF Better

The iShares Russell 1000 Growth ETF (NYSEMKT: IWF) is one of the largest and most popular exchange-traded funds (ETFs) focused…

Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a…

Key deals this week: Couchbase, Eli Lilly, NTT Data, QXO, US Steel and more

…

Lilly expects orforglipron obesity results in third quarter

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the…

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk…

Eli Lilly says India response to obesity drug Mounjaro is positive, will focus on meeting demand

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing…

Missed Out on Eli Lillys 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large…

Missed Out on Eli Lillys 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. @themotleyfool #stocks $VKTX $LLY $ALT

…

Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?

It wasnt so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all…

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

VERV jumps on Eli Lillys buyout offer, adding next-gen gene-editing therapies to the pharma giants pipeline.…

Members of Congress Are Pouring Millions Into These 7 Surprising Stocks

In this video, I will review some of the stock purchases made by members of the U.S. Congress. Politicians such…

Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.…

Lennar, Jabil, Nvidia

Wall Streets main indexes were on track for a lower open on Tuesday as the Israel-Iran conflict entered its fifth…

Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)

…

Eli Lilly lining up $1.3bn swoop for cholesterol specialist Verve

Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3…

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial…

Why Novo Nordisk Stock Sank by Nearly 4% Today

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the…

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the…

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

Youre unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night…

Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical…

1 Growth Stock Down 9% to Buy Right Now

Not many companies that have been around since the late 1800s can claim that theyre growth companies. But Eli Lilly…

Top Analyst Reports for Eli Lilly, Home Depot & SAP

Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and…

Down 12%, Should You Buy the Dip on Eli Lilly? @themotleyfool #stocks $LLY

…

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea,…

2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility

Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date.…

Should You Buy Eli Lilly Stock Before June 22? @themotleyfool #stocks $LLY

…

Drug pricing reform talks with US government lack clarity, industry executives say

Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how…

1 Stock Down 34% This Year to Buy and Hold

Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest…

Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Years 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years

You dont have to be a billionaire to invest like one -- and reap the rewards. Any of us can…

dpa-AFX ProFeed